Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128710 · ClinicalTrials.gov registry record
Prostate Cancer Survey
A clinical trial of Prostate Cancer, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 224
- Enrollment target
- 1
- Study location
NCT03128710 is a study of Prostate Cancer that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 224 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03128710, a study of Prostate Cancer, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 224 participants
- Enrollment target
- 1
- Study location
Study Summary
There have been calls from patients, payers, healthcare providers, and policy makers for an evaluation of newer, high-cost radiation technologies compared to conventional forms of radiation therapy. National attention has focused on the use of intensity modulated radiation therapy (IMRT) into routine daily clinical practice for prostate cancer. The goal of the present study is to determine whether the type of radiation treatment received by the patients can result in a reduction in patient-relevant side effects following prostate irradiation. The analysis will be performed by obtaining patient answered surveys looking at side effects.
Conditions Studied
Study Locations (1)
Maryland
- UMMC - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2018-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03128710
The ClinicalTrials.gov registry entry for NCT03128710 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03128710 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03128710 about?
NCT03128710 is a clinical study titled "Prostate Cancer Survey". There have been calls from patients, payers, healthcare providers, and policy makers for an evaluation of newer, high-cost radiation technologies compared to conventional forms of radiation therapy. National attention has focused on the use of intensity modulated radiation therapy (IMRT) into routin...
What is the current status of trial NCT03128710?
This trial is currently completed. The enrollment target is 224 participants. The study started on 2017-03-15. Estimated completion is 2018-02-15.
What conditions does trial NCT03128710 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT03128710?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03128710 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.